 Connection
Elaine Lam to Drug Administration Schedule
This is a "connection" page, showing publications Elaine Lam has written about Drug Administration Schedule.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.263 |
|
|
|
-
Amirault M, Choo S, Waxweiler T, Weisdack SD, Breaker K, Flaig TW, Lam ET. Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma. Cancer Treat Res Commun. 2021; 27:100367.
Score: 0.162
-
Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, Wei Y, Li X, Bekaii-Saab T, Murgo AJ, Jensen RR, Grever M, Villalona-Calero MA. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1019-29.
Score: 0.075
-
Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|